Publication:
Assessment of the frequency of cardiovascular risk factors in patients with Takayasu's arteritis

Simple item page
dc.contributor.authorÇIKIKÇI, CEYLAN
dc.contributor.authorsAlibaz-Oner, Fatma; Koster, Matthew J.; Unal, Ali U.; Yildirim, Hale G.; Cikikci, Ceylan; Schmidt, Jean; Crowson, Cynthia S.; Makol, Ashima; Ytterberg, Steven R.; Matteson, Eric L.; Direskeneli, Haner; Warrington, Kenneth J.
dc.date.accessioned2022-03-14T08:25:56Z
dc.date.available2022-03-14T08:25:56Z
dc.date.issued2017-11-01
dc.description.abstractObjectives. The prevalence of atherosclerotic risk factors and disease in Takayasu's arteritis (TAK) has not been well defined. We aimed to assess the frequency of cardiovascular (CV) risk factors and the incidence of CV events (CVEs) in patients with TAK from two ethnically different populations. Methods. Patients with TAK followed at Mayo Clinic, Rochester, MN, USA and Marmara University, Istanbul, Turkey were included in this retrospective study. Patients with TAK were compared with age-, sex- and calendar year-matched controls from the same geographical region without TAK. The 2008 Framingham 10-year general CV risk score (FRS) was used for the evaluation of CV risk at the time of TAK incidence/index date. Results. In total, 191 patients with TAK and 191 non-TAK controls were included. Hypertension and the prevalence of lipid-lowering treatments were significantly more frequent in TAK. Prior to the incidence/index date, occurrence of CVE was significantly higher in TAK. The FRS was significantly higher in TAK compared with non-TAK at incidence/index date. The cumulative incidence of CVE was 15.4% at 10 years in TAK vs 5.8% in non-TAK; the risk of CVE was increased among patients with TAK (hazard ratio = 4.36; 95% CI: 1.25, 15.13). Conclusion. CV risk factors are more common in patients with TAK, particularly hypertension. The FRS is higher in patients with TAK at the time of diagnosis. The cumulative incidence of CVE was also significantly higher during follow-up in TAK. Our results suggest that patients with TAK should undergo careful assessment of CV risk factors, and an aggressive risk modification approach is warranted.
dc.identifier.doi10.1093/rheumatology/kex300
dc.identifier.eissn1462-0332
dc.identifier.issn1462-0324
dc.identifier.pubmed28968808
dc.identifier.urihttps://hdl.handle.net/11424/241772
dc.identifier.wosWOS:000413543900015
dc.language.isoeng
dc.publisherOXFORD UNIV PRESS
dc.relation.ispartofRHEUMATOLOGY
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectTakayasu's arteritis
dc.subjectatherosclerotic risk
dc.subjectcardiovascular event
dc.subjectGIANT-CELL ARTERITIS
dc.subjectAUSTRALIAN POPULATION
dc.subjectRHEUMATOID-ARTHRITIS
dc.subjectISCHEMIC EVENTS
dc.subjectDISEASE
dc.subjectATHEROSCLEROSIS
dc.subjectCLASSIFICATION
dc.subjectMORTALITY
dc.subjectDIAGNOSIS
dc.subjectCRITERIA
dc.titleAssessment of the frequency of cardiovascular risk factors in patients with Takayasu's arteritis
dc.typearticle
dspace.entity.typePublication
local.avesis.id44dc5b8d-6179-432d-9b15-5f91a8e3468f
local.import.packageSS16
local.indexed.atWOS
local.indexed.atSCOPUS
local.indexed.atPUBMED
local.journal.numberofpages6
local.journal.quartileQ1
oaire.citation.endPage1944
oaire.citation.issue11
oaire.citation.startPage1939
oaire.citation.titleRHEUMATOLOGY
oaire.citation.volume56
relation.isAuthorOfPublication06f02813-3c4e-47e8-8798-c70712fd7646
relation.isAuthorOfPublication.latestForDiscovery06f02813-3c4e-47e8-8798-c70712fd7646

Files

Collections

Research Outputs